Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-NY-ESO-1 TCR LV-transduced autologous T cells TAEST16001

A preparation of human autologous T lymphocytes that are transduced with a lentiviral vector (LV) encoding an affinity-enhanced T-cell receptor (TCR) specific for the cancer-testis antigen NY-ESO-1, with potential immunostimulating and antineoplastic activities. Upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, the anti-NY-ESO-1 TCR LV-transduced autologous T cells TAEST16001 recognize and bind to NY-ESO-1-overexpressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of NY-ESO-1-positive tumor cells. NY-ESO-1, a tumor-associated antigen (TAA), is found in normal testis and on the surface of various tumor cell types, and is not, or is minimally, expressed in normal, healthy cells.
Synonym:anti-NY-ESO-1 TCR transduced autologous T cells TAEST16001
NY-ESO-1 antigen specific affinity-enhanced TCR transduced autologous T cells
Code name:TAEST 16001
TAEST16001
Search NCI's Drug Dictionary